Charles River Laboratories Price, Chart & Factor Exposure
Free Data & Analytics AccessLatest earnings: November 4, 2026 results vs estimates
Charles River Laboratories Forecast
Charles River Laboratories short-term momentum is strongly positive (up over 4 of 4 look-backs: 5, 10, 20 and 30 trading days), a short-term BUY signal. The long-term trend is strongly positive (8 of 8 checks up: price above, and slope of, its 50-, 100-, 150- and 200-day averages), a long-term BUY signal. Based on 20-day realised volatility of 48.4% a year, a typical one-standard-deviation range is 350.46–401.74 over a week, 323.55–428.65 over a month and 194.05–558.15 over a year. (Signals as of 1 Nov 2026.)
Charles River Laboratories Price Chart
Charles River Laboratories Factors
YoY —
YoY +123.1%
YoY +132.7%
YoY +244.1%
YoY +97.7%
YoY −66.7%
YoY −121.8%
YoY +120.5%
YoY +9.3%
YoY +92.5%
YoY +3.2%
YoY +1.8%
YoY −90.6%
YoY +14.3%
YoY +166.7%
YoY +59.7%
Charles River Laboratories fundamentals: income statement, balance sheet & cash flow
Charles River Laboratories reported revenue of $4.02bn and net income of -$144.3m in FY2025, the year ended 31 December 2025 — revenue down 0.9% and net income down 1,501.7% on the prior year. Free cash flow was $518.5m. These figures are as reported in the filings, not restated: 28 fiscal years and 107 quarters of history, back to December 1998. 173 FINRA short-interest settlements are published alongside them, back to June 2019.
| USD millions | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | 31 Dec 2025 | 31 Dec 2024 | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 |
| Revenue | 4,015.4 | 4,050.0 | 4,129.4 | 3,976.1 | 3,540.2 |
| Cost of revenue | 2,789.8 | 2,718.2 | 2,626.9 | 2,513.4 | 2,205.5 |
| Gross profit | 1,225.6 | 1,331.8 | 1,502.6 | 1,462.7 | 1,334.6 |
| Selling, general & admin. | 723.4 | 751.0 | 750.4 | 665.1 | 619.9 |
| Operating income | 507.8 | 227.3 | 617.3 | 651.0 | 589.9 |
| EBITDA | 410.8 | 581.1 | 1,032.1 | 986.1 | 820.2 |
| Interest expense | 107.0 | 126.3 | 136.7 | 59.3 | 73.9 |
| Pre-tax income | -99.5 | 93.1 | 581.3 | 623.0 | 480.7 |
| Income tax | 42.7 | 67.8 | 100.9 | 130.4 | 81.9 |
| Net income | -144.3 | 10.3 | 474.6 | 486.2 | 391.0 |
Download Charles River Laboratories fundamentals
https://macrofinance.ai/wp-admin/admin-ajax.php?action=mf_fundamentals&symbol=E.CRL.NYSE&statement=all&freq=a&format=csv&years=10
Figures in USD, statements as filed and FINRA consolidated short interest. A cell is left blank where the filing does not report it or where the reported figure fails the statement’s own arithmetic. Short interest is the consolidated FINRA figure for the settlement date shown, published seven to eight business days later.
Research on Charles River Laboratories
Explore MacroFinance macro & markets research and analysis.
Charles River Laboratories Trading Strategies
58 backtested tactical asset allocation strategies hold SPY (US market) or XLV (Health Care sector), the closest tradable exposure to Charles River Laboratories; 28 of them are invested now. Strategies currently invested are listed first.
| Strategy | Style | Rebalance | Now in SPY, XLV | CAGR | Sharpe | Max DD |
|---|---|---|---|---|---|---|
| Tactical Permanent Portfolio | Conservative | Monthly | Premium · upgrade to view | |||
| Zakamulin and Giner's Optimal Trend Following | Moderate | Monthly | Premium · upgrade to view | |||
| Movement Capital's Composite Strategy | Moderate | Monthly | Premium · upgrade to view | |||
| Harry Browne's Permanent Portfolio | Conservative | Monthly | 25% | 7.0% | 0.96 | -17.2% |
| Keller and Van Putten's Flexible Asset Allocation | Moderate | Monthly | Premium · upgrade to view | |||
| Ned Davis' Three Way Model | Moderate | Monthly | Premium · upgrade to view | |||
| 60_40 Benchmark | Moderate | Monthly | 60% | 8.2% | 0.93 | -29.5% |
| Dick Stoken's Active Combined Asset (ACA) - Monthly Trading | Moderate | Monthly | Premium · upgrade to view | |||
| PortfolioCharts' Golden Butterfly | Moderate | Monthly | 20% | 7.4% | 0.91 | -18.0% |
| US Cross-Asset Momentum | Moderate | Monthly | Premium · upgrade to view | |||
Hypothetical backtests over each ETF's own history; past performance does not guarantee future results. Upgrade to see every strategy's allocation and performance.
From creators
- P4 Demo Momentum by admin
- strategyx by admin
Statistical Distribution of Returns
PlusHow Charles River Laboratories’s returns are distributed — and how they change in a given market regime.
Regime filters
| Market/Macro | Indicator | Criteria | Value | And (for Between) | Action |
|---|
No regime filter yet — the chart below shows every period. Add a factor condition, or pick a popular regime.
| Statistic | All periods | Matching |
|---|
About Charles River Laboratories (United States)
Charles River Laboratories is a listed security in the United States. This page shows the latest price and daily change, a price chart, momentum, trend, bubble-risk and volatility signals, its factor exposures, the statistical distribution of its returns, the trading strategies that hold it and free historical data (the last 10 years as CSV or JSON, no login).
Last updated: November 22, 2026
More on Charles River Laboratories
Frequently asked questions
What is Charles River Laboratories?
What is the latest Charles River Laboratories price?
Is Charles River Laboratories in an uptrend?
How volatile is Charles River Laboratories?
What factors affect Charles River Laboratories?
Which trading strategies trade Charles River Laboratories?
How are Charles River Laboratories returns analysed?
Where can I download free Charles River Laboratories historical data?
Free Charles River Laboratories historical data (last 10 years)
Browse or instantly download the last 10 years of Charles River Laboratories daily price history. A free account unlocks the full history, an Excel export with factors, and API access.
https://macrofinance.ai/wp-admin/admin-ajax.php?action=mf_history&symbol=E.CRL.NYSE&format=csv&years=10
| Date | Close |
|---|---|
| 2026-11-20 | 314.32 |
| 2026-11-19 | 327.93 |
| 2026-11-18 | 333.25 |
| 2026-11-17 | 332.16 |
| 2026-11-16 | 335.52 |
| 2026-11-13 | 337.97 |
| 2026-11-12 | 340.81 |
| 2026-11-11 | 342.69 |
| 2026-11-10 | 345.8 |
| 2026-11-09 | 353.34 |
About this stock
Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. The Research Models and Services segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including genetically engineered models and services, insourcing solutions, and research animal diagnostic services; and engages in development and production of cell therapies. The Discovery and Safety Assessment segment offers in vitro and in vivo discovery services for the discovery, development, and safety testing of novel drugs, molecule compounds, oligonucleotides, and biotherapeutics, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services; and vivarium space services. The Manufacturing Solutions segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products; offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies; and contract development and manufacturing products and services. The company has collaborations with Parker Institute for Cancer Immunotherapy and Children's Hospital Los Angeles across its contract development and manufacturing organization; and Medigen Vaccine Biologics Corp for developing next-generation multivalent enterovirus vaccine, enhance global regulatory readiness, and support IND-enabling non-clinical studies. Charles River Laboratories International, Inc. was founded in 1947 and is headquartered in Wilmington, Massachusetts.
See how this market's returns behaved when a factor was in a given state, for example when Momentum was strong or bond yields were above 4%, and compare that with all periods.
Reading the chart
- Each bar is a return bucket; its height is the share of periods that landed there.
- All periods: every return in the date range.
- Matching periods: only the periods where all your filters were true. If orange shifts right of the grey, returns were better in that regime.
- Each period's return is the return over the following day, week or month (set by Timeframe), measured from the day the factor was read, so there is no look-ahead.
Adding a filter
- Factor: grouped the same way as the Factors section on this page (Quantitative, Country, Sector, …). Locked factors are listed but greyed out.
- Criteria: greater (>), greater or equal (≥), equal (=), smaller or equal (≤), smaller (<) or between two values.
- Value: depends on the factor.
- Momentum and Trend are signals from −1 to +1, picked as −100 to +100 in steps of 25.
- Mean Reversion is a z-score of price against its 250-day mean, picked in σ from −3 to +3.
- Everything else is a number you type. The line under the box shows the latest reading and its typical range over the last 10 years.
Add several filters to combine conditions; a period must pass every one. Narrow the window with the From/To dates or the 1Y / 5Y / 10Y / MAX buttons; Clear resets filters and dates.
Return statistics
- Unfiltered vs Filtered: all periods vs matching periods.
- Average return, Std dev and Sharpe are annualised (252 days, 52 weeks, 12 months, 6 two-month periods, 4 quarters).
- Maximum drawdown compounds non-overlapping periods; in the Filtered column it assumes you held only while the condition was true.
- Min, 25th percentile, median, 75th percentile and max are per period, not annualised.